EE200100135A - EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid - Google Patents

EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid

Info

Publication number
EE200100135A
EE200100135A EEP200100135A EEP200100135A EE200100135A EE 200100135 A EE200100135 A EE 200100135A EE P200100135 A EEP200100135 A EE P200100135A EE P200100135 A EEP200100135 A EE P200100135A EE 200100135 A EE200100135 A EE 200100135A
Authority
EE
Estonia
Prior art keywords
eto2c
aze
cgl
pab
crystalline forms
Prior art date
Application number
EEP200100135A
Other languages
English (en)
Inventor
Edvardsson Daniel
Hedstr�m Lena
Lundblad Anita
Pettersson Ursula
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200100135A publication Critical patent/EE200100135A/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
EEP200100135A 1998-09-03 1999-09-02 EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid EE200100135A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802974A SE9802974D0 (sv) 1998-09-03 1998-09-03 New crystalline forms
PCT/SE1999/001514 WO2000014110A1 (en) 1998-09-03 1999-09-02 CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH

Publications (1)

Publication Number Publication Date
EE200100135A true EE200100135A (et) 2002-06-17

Family

ID=20412468

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100135A EE200100135A (et) 1998-09-03 1999-09-02 EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid

Country Status (39)

Country Link
US (5) US6225287B1 (et)
EP (1) EP1107980B1 (et)
JP (2) JP3493341B2 (et)
KR (1) KR100629825B1 (et)
CN (1) CN1204143C (et)
AP (1) AP1520A (et)
AR (1) AR029312A1 (et)
AT (1) ATE231521T1 (et)
AU (1) AU763421B2 (et)
BG (1) BG105384A (et)
BR (1) BR9913464A (et)
CA (1) CA2341259A1 (et)
CU (1) CU23015A3 (et)
CZ (1) CZ2001775A3 (et)
DE (1) DE69905054T2 (et)
DK (1) DK1107980T3 (et)
EA (1) EA003264B1 (et)
EE (1) EE200100135A (et)
ES (1) ES2192101T3 (et)
HK (1) HK1034721A1 (et)
HR (1) HRP20010132B1 (et)
HU (1) HUP0104330A2 (et)
ID (1) ID28779A (et)
IL (1) IL141433A0 (et)
IS (1) IS1942B (et)
MY (1) MY121394A (et)
NO (1) NO20011083L (et)
NZ (2) NZ510070A (et)
OA (1) OA11908A (et)
PL (1) PL346544A1 (et)
SA (1) SA99200682B1 (et)
SE (1) SE9802974D0 (et)
SK (1) SK2802001A3 (et)
TR (1) TR200100700T2 (et)
TW (1) TWI247013B (et)
UA (1) UA66869C2 (et)
WO (1) WO2000014110A1 (et)
YU (1) YU17301A (et)
ZA (1) ZA200101763B (et)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
WO2002030943A1 (fr) * 2000-10-12 2002-04-18 Chugai Seiyaku Kabushiki Kaisha Derive d'erythromycine possedant des nouvelles structures cristallines et procedes associes de production
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
JP4898091B2 (ja) 2002-03-11 2012-03-14 ザ メディシンズ カンパニー (ライプツィヒ) ゲーエムベーハー ウロキナーゼの阻害剤、それらの製造および使用
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
US20050111007A1 (en) * 2003-09-26 2005-05-26 Zetetic Institute Catoptric and catadioptric imaging system with pellicle and aperture-array beam-splitters and non-adaptive and adaptive catoptric surfaces
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
WO2005091696A1 (fr) * 2004-03-29 2005-10-06 Quanta Display Inc. Structure a cadres pour module retroeclaire
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
ES2420989T3 (es) * 2010-02-26 2013-08-28 Biedermann Technologies Gmbh & Co. Kg Implante para estabilizar huesos o vértebras
US9550585B2 (en) 2014-06-09 2017-01-24 Space Systems/Loral, Llc Highly inclined elliptical orbit de-orbit techniques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1075277B (it) * 1977-02-11 1985-04-22 Erba Carlo Spa Derivati insaturi e epossidici dell'acio 7-acilamido-3-cefem-4-carbossilico e procedimento per la loro preparazione
US4315011A (en) * 1978-07-12 1982-02-09 Richter Gedeon Vegyeszeti Gyar Rt. 1-Alkyl-9-bromohexahydroindolo quinolizium salts and use thereof to increase blood flow
GB2096988B (en) * 1980-11-20 1984-08-01 Beecham Group Ltd Aromatic hydroxyamines
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE504185C2 (sv) * 1994-11-08 1996-12-02 Astra Ab Lagringsstabil vattenlösning för infusion av trombininhibitorer
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
US5830805A (en) * 1996-11-18 1998-11-03 Cornell Research Foundation Electroless deposition equipment or apparatus and method of performing electroless deposition
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms

Also Published As

Publication number Publication date
US20010023244A1 (en) 2001-09-20
CN1325406A (zh) 2001-12-05
EA200100194A1 (ru) 2001-10-22
SA99200682B1 (ar) 2006-08-22
US6440939B2 (en) 2002-08-27
KR100629825B1 (ko) 2006-09-29
NZ524486A (en) 2004-10-29
US20060287249A1 (en) 2006-12-21
IS1942B (is) 2004-08-13
YU17301A (sh) 2004-05-12
AR029312A1 (es) 2003-06-25
US6888007B2 (en) 2005-05-03
US20050054579A9 (en) 2005-03-10
HRP20010132A2 (en) 2002-02-28
AU763421B2 (en) 2003-07-24
HK1034721A1 (en) 2001-11-02
AU6014799A (en) 2000-03-27
AP1520A (en) 2005-12-28
EA003264B1 (ru) 2003-02-27
PL346544A1 (en) 2002-02-11
ATE231521T1 (de) 2003-02-15
US20030017992A1 (en) 2003-01-23
HRP20010132B1 (en) 2004-06-30
NO20011083D0 (no) 2001-03-02
IS5870A (is) 2001-02-28
EP1107980A1 (en) 2001-06-20
US20050153901A1 (en) 2005-07-14
ID28779A (id) 2001-07-05
KR20010088795A (ko) 2001-09-28
ES2192101T3 (es) 2003-09-16
JP2002524467A (ja) 2002-08-06
UA66869C2 (uk) 2004-06-15
NO20011083L (no) 2001-05-03
CA2341259A1 (en) 2000-03-16
CZ2001775A3 (cs) 2001-10-17
EP1107980B1 (en) 2003-01-22
AP2001002078A0 (en) 2001-03-31
BR9913464A (pt) 2001-06-12
MY121394A (en) 2006-01-28
US6225287B1 (en) 2001-05-01
ZA200101763B (en) 2002-06-03
TR200100700T2 (tr) 2001-07-23
DE69905054D1 (de) 2003-02-27
BG105384A (en) 2001-11-30
NZ510070A (en) 2003-04-29
JP2004075687A (ja) 2004-03-11
DK1107980T3 (da) 2003-04-22
CN1204143C (zh) 2005-06-01
HUP0104330A2 (hu) 2002-04-29
SK2802001A3 (en) 2001-09-11
WO2000014110A1 (en) 2000-03-16
OA11908A (en) 2006-04-10
SE9802974D0 (sv) 1998-09-03
DE69905054T2 (de) 2003-11-06
TWI247013B (en) 2006-01-11
JP3493341B2 (ja) 2004-02-03
CU23015A3 (es) 2005-01-25
IL141433A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
ID27092A (id) Pembuatan ftalat anhidrida
LTC1124961I2 (lt) Trombopoetino junginiai
ATE229954T1 (de) Betacarbolinverbindungen
ID28266A (id) Senyawa-senyawa amidin
BR9711151A (pt) Forma cristalina de 4-¬5-metil-3-fenilsoxazol-4-il¾benzenossulfonamida
PT1119430E (pt) Fresa
PT1100326E (pt) Microcapsulas de libertacao activada por bases
ID27004A (id) Senyawa-senyawa kalsilitik
NO20006255D0 (no) Krystallinsk efavirenz
DE69903524D1 (de) Pestizide hilfsmittel
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
FI980222A0 (fi) Stycke av isoleringsaemne med en genomgaoende primaerstroemledning
IS5821A (is) Kristalluð form af ósanetant
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
PT1175417E (pt) Compostos substituidos de benzolactamas
FI980856A0 (fi) Andningsskydd utrustad med en identifierare
NO20004583D0 (no) Krystallinsk form av paroxetine
SI1107980T1 (en) CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH
IT1304635B1 (it) Mezzi di raccordo
IDP000021799A (id) Senyawa-senyawa pirolum tersubstitusi
IDP000021790A (id) Senyawa-senyawa pirolum tersubstitusi
SE9800458D0 (sv) Novel compounds
SE9803669D0 (sv) Novel compounds
SE9801397D0 (sv) Novel compounds